Premium
Inflammatory biomarkers in Alzheimer's disease plasma
Author(s) -
Morgan Angharad R.,
Touchard Samuel,
Leckey Claire,
O'Hagan Caroline,
NevadoHolgado Alejo J.,
Barkhof Frederik,
Bertram Lars,
Blin Olivier,
Bos Isabelle,
Dobricic Valerija,
Engelborghs Sebastiaan,
Frisoni Giovanni,
Frölich Lutz,
Gabel Silvey,
Johannsen Peter,
Kettunen Petronella,
Kłoszewska Iwona,
LegidoQuigley Cristina,
Lleó Alberto,
MartinezLage Pablo,
Mecocci Patrizia,
Meersmans Karen,
Molinuevo José Luis,
Peyratout Gwendoline,
Popp Julius,
Richardson Jill,
Sala Isabel,
Scheltens Philip,
Streffer Johannes,
Soininen Hikka,
TaintaCuezva Mikel,
Teunissen Charlotte,
Tsolaki Magda,
Vandenberghe Rik,
Visser Pieter Jelle,
Vos Stephanie,
Wahlund LarsOlof,
Wallin Anders,
Westwood Sarah,
Zetterberg Henrik,
Lovestone Simon,
Morgan B. Paul
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.03.007
Subject(s) - biomarker , oncology , context (archaeology) , medicine , cohort , apolipoprotein e , logistic regression , alzheimer's disease , immunology , disease , biology , genetics , paleontology
Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a “Holy Grail” of AD research and intensively sought; however, there are no well‐established plasma markers. Methods A hypothesis‐led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262) subjects from AddNeuroMed. Results Ten analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP‐1, eotaxin‐1) that, age/APOε4 adjusted, optimally differentiated AD and CTL (AUC: 0.79), and three (sCR1, MCP‐1, eotaxin‐1) that optimally differentiated AD and MCI (AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH) plus age predicted MCI progression to AD (AUC: 0.71). Discussion Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation.